Related Posts
Protecting IgA Nephropathy Patients: Sparsentan Reduces Proteinuria and Preserves Kidney Function Through to Two Years
ISN-ACT Global Trials Focus editorial team member Neeru Agarwal summarizes the... read more
ETAR Blockade’s Role in Current and Emerging Therapies for IgAN- Explore the Visual Abstract
Click on the image to expand This visual abstract was supported by... read more
A Ray of Light for People Living With Chronic Kidney Disease: A Promising Digital Physical Activity Intervention
ISN-ACT Global Trials Focus editorial team member Megan Borkum summarizes the... read more
Sparsentan Decreased Proteinuria, but Failed to Slow eGFR Decline in FSGS: Data From the DUPLEX Trial – New Selection of Global Trials Out Now!
ISN-ACT Global Trials Focus Subgroup member Anastasiia Zykova summarizes the design... read more
The Lancet Global Health Publishes ISN Paper on Global Insights From the 2023 ISN-Global Kidney Health Atlas
The paper "An Update on the Global Disparities in Kidney Disease... read more
Expanding Skills and Knowledge in Key Areas of Kidney Care: Access Three New ISN Implementation Toolkits
As part of the ISN-WHO 2021-2023 collaboration plan, the ISN is... read more
“An Essential Advocacy Tool That Young Nephrologists Should Wholeheartedly Endorse”: Yannick Nlandu on the ISN-Global Kidney Health Atlas
By Yannick Nlandu (DR Congo), YNC member and ISN-GKHA Named Fellow... read more
Demystifying Global Kidney Trials: Providing Clear Explanations for All With a New ISN Patient-Focused Initiative
Discover the "ISN Global Kidney Trials Insights: A Guide for Everyone,"... read more
ETAR Blockade’s Role in Current and Emerging Therapies for IgAN– Explore the Visual Abstract
This visual abstract was supported by an unrestricted educational grant from... read more
What is the ISN Doing About the Challenge of Chronic Kidney Disease of Unknown Origin?
Despite ongoing efforts, chronic kidney disease of unknown origin (CKDu) remains... read more